Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HP-3150 (sufentanil)
- Development stage
- Approved
- Lead developer
- Hisamitsu Pharmaceutical
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
HP-3150 (Dofenta) is a transdermal patch formulation of sufentanil, a potent synthetic opioid analgesic, developed by Hisamitsu Pharmaceutical. Utilizing Hisamitsu's proprietary transdermal drug delivery system (TDDS) technology, the patch is designed to provide stable and continuous systemic delivery of sufentanil for the management of cancer-related pain. Sufentanil is a highly selective mu-opioid receptor agonist with a potency significantly greater than that of fentanyl or morphine. This formulation offers a non-invasive treatment option for patients with moderate-to-severe chronic pain, particularly those who have difficulty with oral administration. HP-3150 was approved for manufacturing and marketing in Japan in March 2024 for the treatment of cancer pain.
- Brand names
- Dofenta
- Other names
- sufentanil citrateDofenta Tape
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on HP-3150 (sufentanil).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HP-3150 (sufentanil).